Shoppers of capital markets are watching datacentre deals reshape portfolios; investors cheered a newly signed 555MW CDC contract that boosts contracted capacity past one gigawatt, tightens growth visibility for Infratil and lifts NZ stocks. This matters because it derisks CDC’s build‑out, signals bigger 2028 earnings and helps explain recent market moves.
Essential Takeaways
- Big contract: CDC signed a 555MW data‑centre contract, taking its total contracted capacity beyond 1GW.
- Material scale: The 555MW is roughly 40% of Australia’s operating datacentre capacity in 2025, a chunky share.
- Earnings lift: CDC’s 2027 ebitdaf guidance stayed at A$680m–A$720m, with 2028 expected to exceed A$1bn and long‑term annualised ebitdaf potentially around A$2bn.
- Infratil impact: Infratil, holding 49.72% of CDC, has seen revaluation gains and a boost in market cap, briefly becoming the third‑largest NZ stock.
- Practical note: The contract capacity will be delivered across datacentres coming online in 2028–29, so investors should watch construction milestones and customer commissioning.
Why the 555MW deal matters now
The headline number is impressively tactile , half a gigawatt plus , and it changes the math for CDC and its shareholders. According to CDC’s announcement, the new contract pushes contracted capacity above 1GW, which is a clear signal that customers are committing to large blocks of infrastructure. Investors liked the visibility; Infratil shares jumped and analysts marked up valuations. For anyone tracking the datacentre and AI infrastructure boom, this is the kind of proof point that turns strategy talk into dollars.
How this derisks CDC’s growth story
Before the signing, some observers were asking when the big deals would arrive. The contract gives CDC a clear runway: revenues and ebitdaf are now more predictable as capacity is locked to customers. Infratil and other backers already put A$500m into accelerating CDC’s build programme, and management expects full deployment to support much higher earnings in coming years. That lowers execution risk, though the company still needs to deliver complex construction projects on time.
Where the money and capacity come together
CDC plans to deliver this capacity across datacentres under development, with facilities becoming operational in 2028 and 2029. That timeline matters for cashflow and for investors expecting near‑term returns. Capital expenditure is substantial , billions across the programme , and shareholders will be watching milestones and early commissioning closely. If sites come online as planned, CDC’s contracted revenue should start to flow and justify the earlier funding injections.
Market ripple effects in New Zealand and beyond
The deal didn’t just help CDC; it lifted Infratil’s share price enough for the company to overtake a major listed asset and become the third‑largest NZ stock by market capitalisation. That’s a neat reminder that big infrastructure contracts can have outsized effects on parent companies. Elsewhere, tech and AI spending is lifting markets globally, with US indices also pushing to new highs. For local investors, it’s a reason to re‑examine portfolio exposure to infrastructure and AI‑linked real estate.
What to watch next , practical investor checklist
Look for construction and commissioning updates, milestone revenue recognition, and any changes to CDC’s guidance. Keep an eye on Infratil’s disclosure of revaluation gains and how much of CDC’s future ebitdaf is reflected in market prices. If you’re choosing where to gain exposure, consider timing: much of the revenue lift is tied to 2028–29 operations, so short‑term volatility is possible while the build‑out continues.
It's a tangible win for CDC and Infratil, and a reminder that large customer commitments can pivot an entire sector's outlook.
Source Reference Map
Story idea inspired by: [1]
Sources by paragraph: